• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1.5 Contact Hour(s)

    Release Date

    Wednesday, November 14, 2018

    Offline Date

    Monday, May 13, 2019

    ACPE Expiration Date

    Monday, June 28, 2021

    Target Audience

    Pharmacist, Pharmacy Technician, Nurse

    Cost

    $0.00

    • Overview

      Diabetes treatment options continue to expand. While this allows providers to have a larger armamentarium for treatment, questions still remain about the best option(s) to use in certain patients. Clinical inertia related to progressive diabetes management also exists for many patients and providers, making successful glycemic control even more difficult. This program will provide and overview of strategies used for recognizing and overcoming clinical inertia. It will also provide an overview of commonly used diabetes treatment options, and focus on which options are best for certain patients.

      30 days following this live webinar, participants will be invited to participate in a 30-minute follow-up home study (0.5 credit hour) that will provide the opportunity to review the main concepts from the webinar and apply what has been learned to patient cases related to diabetes treatment options.in patients.

      Handouts

      • Slide Document :   18098H01_4pp.pdf
      • Slide Document :   18098H01_2pp.pdf

      Financial Support By

      Merck & Co., Inc
    • Pharmacist

      Compare key medication - and disease-specific considerations for selecting adjunct diabetes treatments
      Identify clinical situations appropriate for early initiation of adjunct diabetes treatment options
      Examine benefits incurred with the early initiation of adjunct diabetes treatments
      Explain the effect clinical inertia can have on the management of diabetes mellitus

      Pharmacy Technician

      State benefits of early initiation of adjunct diabetes treatments
      Identify pharmacist referral opportunities in which early initiation of diabetes education may be beneficial to a patient
      Define clinical inertia and describe its potential impact to a patient
      Identify and categorize key medications commonly used in the treatment of diabetes by brand name, generic name, and drug classification

      Nurse

      Examine benefits incurred with the early initiation of adjunct diabetes treatments
      Compare key medication - and disease-specific considerations for selecting adjunct diabetes treatments
      Identify clinical situations appropriate for early initiation of adjunct diabetes treatment options
      Explain the effect clinical inertia can have on the management of diabetes mellitus
    • Activity Type

      Application

      CE Broker

      20-657320

      Universal Activity Number

      Pharmacist 0798-0000-18-098-H01-P
      Pharmacy Technician 0798-0000-18-098-H01-T
      Nurse 0798-0000-18-098-H01-P

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).